{"id":951426,"date":[{"year":1994,"month":8,"day":2}],"page":"5","source":"本报","region":"","masthead":"长江新潮","special_issue":"长江新潮","column":"","genre":"","count":"236","ytitle":"","mtitle":"《威利宁》开发成功","ftitle":"","authors":[],"text":[{"type":"paragraph","text":"本报讯　复旦大学和浙北制药厂通过多年研究，开发成功抗病毒新药威利宁。威利宁的主要成份利巴韦林，是一种能抑制多种RNA病毒和DNA病毒的核苷类抗病毒化合物，具有广谱抗病毒作用，且副作用小，多种给药途径均有效，不产生抗药性。浙北制药厂在用新技术生产利巴韦林原料药基础上继续研制成威利宁新药。威利宁通过多家医院临床验证，治疗病毒性呼吸道感染总有效率为80%，治疗甲型肝炎总有效率为100%，治疗流行性出血热总有效为100%，治疗带状疱疹总有效率为75%。"}]}